No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland. Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders. Mesoblast's distinctive regenerative medicine platform is founded on the therapeutic potential of specialized mesenchymal lineage cells. A prominent candidate, Remestemcel-L, is currently in late-stage (Phase III) clinical trials for various systemic inflammatory conditions, such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic-refractory inflammatory bowel disease. Additionally, Remestemcel-L is undergoing Phase III evaluation for chronic heart failure and chronic low back pain linked to degenerative disc disease. The company's pipeline also features MPC-300-IV, under development for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC, aimed at treating or preventing acute myocardial infarction. Mesoblast has forged key strategic partnerships, including one with Tasly Pharmaceutical Group for the commercialization of MPC-150-IM (for heart failure) and MPC-25-IC (for heart attacks) in China. It also collaborates with JCR Pharmaceuticals Co. Ltd. on wound healing therapies for epidermolysis bullosa patients, and with Grünenthal to advance and market a cell therapy for chronic low back pain.
www.mesoblast.comNo one on the platform currently holds MSB.AX.
No tracked institution reports a position in MSB.AX as of their last filing.
No one on the platform has traded MSB.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 614.6% | 75.1% | ||||
| Profit Margin % | -47.8% | -823.7% | -961.1% | |||
| Free Cash Flow Margin % | -36.4% | -530.4% | -903.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $183M | +45.8% | $-0.02 | $-0.13–$0.15 | — | 3 |
| 2028 | $291M | +59.3% | $0.02 | $-0.00–$0.04 | — | 4 |
| 2029 | $497M | +70.6% | $0.13 | $0.01–$0.29 | — | 4 |
| 2030 | $856M | +72.3% | $0.31 | $0.13–$0.77 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-26 | $-0.01 | $-0.02 | -23.2% |
| 2026-02-26 | $-0.04 | $-0.05 | -31.2% |
| 2025-08-28 | $-0.06 | $-0.07 | -15.2% |
| 2025-04-30 | $-0.06 | $-0.04 | +36.9% |
| 2025-02-26 | $-0.56 | $-0.07 | +87.9% |
| 2024-10-31 | $-0.19 | $-0.04 | +78.9% |
| 2024-08-28 | $-0.19 | $-0.04 | +78.9% |
| 2024-04-30 | $-0.07 |
| $-0.04 |
| +45.2% |
| +2.33% |
| $130M |
| — |
| IMM.AXImmutep Limited | $0.04 | +0.00% | $66M | — |
| NEU.AXNeuren Pharmaceuticals Limited | $20.57 | -0.72% | $2.6B | — |
Source: Financial Modeling Prep · peers by sector/industry